Actively Recruiting
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Led by Juan P. Alderuccio, MD · Updated on 2026-03-23
100
Participants Needed
5
Research Sites
441 weeks
Total Duration
On this page
Sponsors
J
Juan P. Alderuccio, MD
Lead Sponsor
A
ADC Therapeutics S.A.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.
CONDITIONS
Official Title
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women 18 years of age or older
- Histologic confirmation of follicular lymphoma (grades 1, 2, or 3A)
- Relapsed or refractory follicular lymphoma previously treated with at least one line of systemic therapy and meeting at least one Groupe d'Etude des Lymphomes (GELF) criteria for therapy, or disease progression within 24 months of frontline treatment, or second relapse
- Baseline FDG-PET/CT scans showing positive lesions compatible with CT-defined tumor sites with at least one measurable disease site per Lugano classification
- At least one GELF criteria for treatment initiation, including involvement of 3 or more nodal sites of 3 cm or larger, tumor mass 7 cm or larger, B symptoms, risk of organ compromise, splenomegaly or splenic lesion, leukopenia, leukemia, or bone lesions
- Progression or relapse within 24 months of frontline treatment after at least one line of systemic therapy, or second follicular lymphoma relapse/progression after at least one line of systemic therapy regardless of GELF criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
- Life expectancy greater than 6 weeks
- Normal organ and marrow function as defined by specific blood count, liver function, and kidney function thresholds
You will not qualify if you...
- Follicular lymphoma grade 3B or transformed follicular lymphoma
- Six or more lines of systemic immunochemotherapy for follicular lymphoma
- Clinically significant pleural effusions or ascites requiring drainage or causing shortness of breath
- Receiving any other investigational agents
- Known central nervous system involvement of lymphoma
- Uncontrolled illnesses including recent heart attack, severe heart failure, uncontrolled arrhythmia, recent stroke, liver cirrhosis, or autoimmune disorders requiring immunosuppression or high-dose corticosteroids
- Pregnant or breastfeeding women
- Active hepatitis B or C infection as defined by positive PCR tests
- History of HIV infection
- Impaired decision-making capacity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Florida Cancer Specialists and Research Institute
Fort Myers, Florida, United States, 33916
Not Yet Recruiting
2
University of Miami
Miami, Florida, United States, 33136
Actively Recruiting
3
University of Michigan
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
4
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901
Actively Recruiting
5
Allegheny Health Network
Pittsburgh, Pennsylvania, United States, 15212
Not Yet Recruiting
Research Team
J
Juan P Alderuccio, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here